Jagsonpal Pharmaceuticals Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 26 May 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹1.5K Cr
Management expects growth acceleration to double digits starting Q4 FY‘26. The company aims for double-digit growth starting Q4 FY '26, targeting over 10% growth, above the industry's 7.5%-8.5% expected growth.
From Jagsonpal Pharmaceuticals Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹237
Market Cap
₹1.5K Cr
P/E Ratio
31.8
How does Jagsonpal Pharmaceuticals Ltd rank in Pharmaceuticals & Biotechnology?
Compare Jagsonpal Pharmaceuticals Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Jagsonpal Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹64 Cr, net profit ₹9 Cr.
Full financials →📊 Revenue & Sales Performance
- →Management expects growth acceleration to double digits starting Q4 FY‘26.
- →Industry growth rate assumed around 7.5%-8.5%, with company targeting 50% higher growth than the industry, i.e., above 10%.
- →Long-term outlook remains steady organic growth of 12%-14% over 3-4 years, barring macro/external changes.
- →Growth to be driven by both volume expansion and price increases, with new product launches contributing significantly.
- →Volume growth is expected to improve, supported by increased prescriber base and prescriptions per doctor.
- →Strategic resource reallocation and brand rationalization aims to focus on larger, high-growth brands.
- →Launch of high-growth products expected around end of H1 FY‘27 to boost volume and value.
- →Management confident of improved per capita productivity of field force to support growth.
📈 Profitability & Margins
- →The company aims for double-digit growth starting Q4 FY '26, targeting over 10% growth, above the industry's 7.5%-8.5% expected growth.
- →Long-term organic growth outlook remains positive with a target of 12%-14% CAGR over 3-4 years, barring macro changes.
- →Volume growth and new product launches alongside price increases are key drivers; volume expected to improve alongside new product introductions.
- →Per capita sales and field force productivity improvements are underway to boost prescription growth.
- →Acquisitions like Yash Pharma have contributed positively and may support further growth; however, disciplined, value-accretive M&A is a priority.
- →Margins improved with operational resilience; EBITDA margins were 22.6% for nine months FY '26.
- →Management is confident of sustained improvement and growth acceleration from the coming financial year and beyond.
🏗️ Capital Expenditure Plans
- →Jagsonpal Pharmaceuticals follows an asset-light model with most manufacturing outsourced, implying limited need for large capex.
- →The company is focused on strategic capital deployment, primarily through acquisitions that are EBITDA accretive and value-adding.
- →Currently, the management is seriously looking at acquisition candidates but notes that assets are highly priced, so disciplined M&A is key.
- →Apart from acquisitions, some capital may be deployed towards organic growth in the form of product launches in high growth areas expected by end of H1 FY 2027.
- →If suitable acquisitions are not found, the company may consider returning cash to shareholders.
- →No plans for salesforce rationalization or large-scale distribution expansion capex currently.
- →Depreciation rise mainly due to intangible assets from acquisitions (e.g., Yash Pharma), not from increased fixed asset investment.
💰 Fundraising & Capital Structure
- →The management did not mention any current or immediate plans for fundraising through debt or equity during the call.
- →They emphasized disciplined capital allocation, focusing on meaningful, EBITDA-accretive M&A opportunities.
- →Due to high asset prices, they are cautious and selective about acquisitions.
- →If suitable acquisitions are not found, they prefer returning cash to shareholders rather than inefficient deployment.
- →The company follows an asset-light model and generates significant cash internally.
- →Overall, there is no indication of imminent debt or equity fundraising planned.
📋 Order Book & Pipeline
Key Metrics
Continue your research
What Jagsonpal Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- OneSource Specialty Pharma Ltd (Q3 FY26)
OneSource Specialty Pharma is aggressively investing in capacity expansion with over INR 700 crores (approximately $100 million) planned for flagship site…
- Mankind Pharma Ltd (Q3 FY26)
Overall domestic prescription business growth for Q3 was 9%+ and 8.2% for 9 months (excluding OTC), indicating steady growth. Key concall takeaways from…
- Gland Pharma (Q3 FY26)
Investments of INR 2,000 crores over next 5 years, including Brownfield expansions, BFS lines, and ophthalmic lines, to enhance capacity and drive volume/value…
- Shilpa Medicare Ltd (Q3 FY26)
Formulation business growing robustly, with 104% quarter-on-quarter growth excluding licensing income. Key concall takeaways from Shilpa Medicare's Q3 FY26…
Frequently Asked Questions
What were Jagsonpal Pharmaceuticals Ltd Q3 FY26 results?
Management expects growth acceleration to double digits starting Q4 FY‘26. The company aims for double-digit growth starting Q4 FY '26, targeting over 10% growth, above the industry's 7.5%-8.5% expected growth.
What is Jagsonpal Pharmaceuticals Ltd share price analysis?
Jagsonpal Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 31.8 with a market cap of ₹1,494 Cr. Investors should review the full earnings analysis for detailed insights.
Is Jagsonpal Pharmaceuticals Ltd planning capital expenditure?
Jagsonpal Pharmaceuticals follows an asset-light model with most manufacturing outsourced, implying limited need for large capex.
Keep Jagsonpal Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.